These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18686218)

  • 21. Editorial comment.
    Walson PD; Mullins CD; Lyles A; West JA
    Clin Ther; 2008 Oct; 30(10):1889. PubMed ID: 19014844
    [No Abstract]   [Full Text] [Related]  

  • 22. [Investigation today for practice tomorrow].
    Klein H
    Dtsch Med Wochenschr; 2013 May; 138(18):933. PubMed ID: 23613370
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of models within economic analysis: focus on type 2 diabetes mellitus.
    Coyle D; Lee KM; O'Brien BJ
    Pharmacoeconomics; 2002; 20 Suppl 1():11-9. PubMed ID: 12036380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The German diabetes dilemma: DMP: insufficient management of the diabetic patient in general practice?].
    MMW Fortschr Med; 2005 Oct; 147(41):10. PubMed ID: 16270503
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
    J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria.
    Postma MJ; Boersma C; Gansevoort RT
    Nephrol Dial Transplant; 2008 Apr; 23(4):1103-6. PubMed ID: 17210586
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of diabetes education.
    Urbanski P; Wolf A; Herman WH
    J Am Diet Assoc; 2008 Apr; 108(4 Suppl 1):S6-11. PubMed ID: 18358259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Basal insulin in discussion--clinical and health economics aspects].
    Middeke M
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
    [No Abstract]   [Full Text] [Related]  

  • 32. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.
    Vondeling H; Iversen PB
    Eur J Health Econ; 2004 Oct; 5(3):263-9. PubMed ID: 15714347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in use of high-cost diabetes mellitus medications in the VA healthcare system.
    Gellad W; Mor M; Zhao X; Donohue J; Good C
    Arch Intern Med; 2012 Nov; 172(20):1608-9. PubMed ID: 23044980
    [No Abstract]   [Full Text] [Related]  

  • 34. [What are the costs of type-2 diabetes? Pharmacoeconomics].
    Verspohl EJ
    Pharm Unserer Zeit; 2002; 31(3):308-11. PubMed ID: 12071128
    [No Abstract]   [Full Text] [Related]  

  • 35. Type 2 diabetes market.
    Gershell L
    Nat Rev Drug Discov; 2005 May; 4(5):367-8. PubMed ID: 15902771
    [No Abstract]   [Full Text] [Related]  

  • 36. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
    Crasto W; Jarvis J; Hackett E; Nayyar V; McNally PG; Davies MJ; Lawrence IG
    Postgrad Med J; 2009 Apr; 85(1002):219-22. PubMed ID: 19417173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes research in health care: simulations to drive cost conclusions.
    Frear R; Motheral B
    Value Health; 2004; 7(1):11-2. PubMed ID: 14720126
    [No Abstract]   [Full Text] [Related]  

  • 38. [Who should be responsible for the treatment of type 2 diabetes?].
    Ostgren CJ; Eliasson B
    Lakartidningen; 2008 Sep 3-9; 105(36):2432-3. PubMed ID: 18831458
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
    Simoens S
    Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New agents in the management of type 2 diabetes: do they provide an opportunity for a shift in the treatment paradigm?
    Valdez CA
    J Manag Care Pharm; 2008 Sep; 14(7):650-4. PubMed ID: 18774875
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.